FACS analysis shows that Human CD40, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. CD0-H525a) can bind to 293T cells overexpressing human CD40L. The concentration of Human CD40 is 0.03 μg/ml (Routinely tested).
Loaded Human CD40, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. CD0-H525a) on Protein A Biosensor, can bind Human CD40 Ligand, His,Flag Tag (active trimer) (MALS verified) (Cat. No. CDL-H52Db) with an affinity constant of 0.911 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Loaded Rhesus macaque CD40, Fc Tag (Cat. No. CD0-C5259) on Protein A Biosensor, can bind Human CD40 Ligand, His,Flag Tag (active trimer) (MALS verified) (Cat. No. CDL-H52Db) with an affinity constant of 0.829 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
FFP-102 | 5-D12; PG-102 | Phase 2 Clinical | Pangenetics | Arthritis, Psoriatic; Crohn Disease | Details |
SHR-1704 | SHR-1704 | Phase 1 Clinical | Hematologic Diseases | Details | |
CD40.HIVRI.Env Vaccine | Phase 1 Clinical | HIV Infections | Details | ||
BI-655064 | BI-655064 | Phase 2 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Purpura, Thrombocytopenic, Idiopathic; Arthritis, Rheumatoid; Lupus Nephritis | Details |
FFP-104 | FFP-104 | Phase 2 Clinical | Ff Pharma | Liver Cirrhosis, Biliary; Crohn Disease | Details |
2141-V11 | 2141-V11 | Phase 1 Clinical | Darell Bigner | Ganglioglioma | Details |
Bleselumab | 4D-11; ASKP-1240 | Phase 2 Clinical | Kyowa Hakko Kogyo | Rejection of renal transplantation; Rejection of organ transplantation; Glomerulosclerosis, Focal Segmental; Psoriasis | Details |
SEA-CD40 | SEA-CD40 | Phase 2 Clinical | Seattle Genetics | Lymphoma, B-Cell; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Neoplasms, Squamous Cell; Pancreatic Neoplasms; Lymphoma, Follicular; Lymphoma; Lymphoma, Non-Hodgkin; Carcinoma, Squamous Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
Autologous IL2 and CD40 ligand-expressing tumor cells (Baylor College of Medicine) | Phase 1 Clinical | Baylor College Of Medicine | Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Ravagalimab | ABBV-323; PR-1629977 | Phase 2 Clinical | Abbvie Inc | Colitis, Ulcerative | Details |
Anti-CD40 ChiLob7/4 (BioNTech) | Phase 2 Clinical | Biontech Se | Head and Neck Neoplasms; Pancreatic Neoplasms | Details | |
Mitazalimab | ADC-1013; JNJ-7107; JNJ-64457107 | Phase 2 Clinical | Alligator Bioscience | Solid tumours; Carcinoma, Pancreatic Ductal | Details |
CD40L-GVAX | GM.CD40L; CD40L-GVAX; GM-CSF/CD40L; hCD40L/hGM-CSF | Phase 2 Clinical | University Of South Florida | Myelodysplastic Syndromes; Lung Neoplasms; Melanoma | Details |
MEDI-5083 | MEDI-5083 | Phase 1 Clinical | Astrazeneca Plc, Medimmune | Solid tumours | Details |
RO-7300490 | RO-7300490; RG-6189 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours | Details |
BSI-038 | BSI-038 | Phase 1 Clinical | Boaoxin Biotechnology(Nanjing) Co Ltd | Solid tumours | Details |
CDX-1140 | CDX-1140 | Phase 2 Clinical | Celldex Therapeutics | Lymphoma, Follicular; Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma; Lymphoma, Non-Hodgkin; Fallopian Tube Neoplasms; Waldenstrom Macroglobulinemia; Colorectal Neoplasms; Peritoneal Neoplasms; Lymphoma, Mantle-Cell; Breast Neoplasms; Cholangiocarcinoma; Solid tumours; Urinary Bladder Neoplasms; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Lymphoma, B-Cell; Head and Neck Neoplasms; Ovarian Neoplasms; Liver Neoplasms; Lymphoma, B-Cell, Marginal Zone | Details |
LVGN-7409 | LVGN7409; LVGN-7409 | Phase 1 Clinical | Lyvgen Biopharma(HK)Ltd | Neoplasms | Details |
SL-172154 | SL-172154 | Phase 1 Clinical | Shattuck Labs Inc | Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Peritoneal Neoplasms; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms | Details |
MP-0317 | MP-0317 | Phase 1 Clinical | Molecular Partners Ag | Solid tumours; Neoplasms | Details |
YH-003 | YH-003; YH003 | Phase 2 Clinical | Eucure Pharmaceutical Technology (Beijing) Co Ltd | Solid tumours; Pancreatic Neoplasms; Carcinoma, Pancreatic Ductal; Melanoma | Details |
Tecaginlimab | BNT-312; GEN-1042 | Phase 2 Clinical | Genmab | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
KPL-404 | KPL-404 | Phase 2 Clinical | Kiniksa Pharmaceuticals Ltd | Arthritis, Rheumatoid | Details |
Sotigalimab | APX-005; APX-005M; EPI-0050 | Phase 2 Clinical | Epitomics | Head and Neck Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Microsatellite Instability; Sarcoma; Brain Neoplasms; Glioma; Lung Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
Giloralimab | ABBV-927 | Phase 2 Clinical | Abbvie Inc | Head and Neck Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
NJA-730 | NJA-730; NJA-730a; NJA-730b | Phase 1 Clinical | Napajen Pharma | Graft vs Host Disease; Autoimmune Diseases of the Nervous System | Details |
Iscalimab | CFZ-533; NVP-CFZ533; OM11-62-MF | Phase 2 Clinical | Novartis Pharma Ag | Rejection of renal transplantation; Myasthenia Gravis; Diabetes Mellitus, Type 1; Rejection of liver transplantation; Arthritis, Rheumatoid; Sjogren's Syndrome; Lupus Nephritis; Lupus Erythematosus, Systemic; Graves Disease; Sjogren-Larsson Syndrome; Hidradenitis Suppurativa | Details |
TQB-2916 | TQB2916; TQB-2916 | Phase 1 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Neoplasms | Details |
MIL-97 | MIL-97 | Phase 1 Clinical | Beijing Mabworks Biotech Co Ltd | Solid tumours | Details |
This web search service is supported by Google Inc.